Fungal infections in pediatric intensive care units

Gabriele Finco; Daniela Sanna; Maurizio Evangelista; Paolo Mura; Mario Musu

doi:10.3109/14767058.2011.601922

Fungal infections in pediatric intensive care units

Gabriele Finco, Daniela Sanna, Maurizio Evangelista, Paolo Mura, Mario Musu

Università Cattolica del Sacro Cuore

University of Cagliari

Risultato della ricerca: Contributo in rivista › Articolo in rivista › peer review

3 Citazioni (Scopus)

Abstract

Pediatric fungal infections are associated with significant morbidity and mortality. Few adequately powered antifungal trials have been performed in neonates and children. Neonatologists and pediatricians are reliant on adult trials when managing candidemia. Recent guidelines from the Infectious Diseases Society of America recommend fluconazole or an echinocandin for empiric therapy in suitable candidates, with a preference for an echinocandin in patients with moderate-to severe disease, recent azole exposure, or high risk of C. glabrata or C. krusei infection

Lingua originale	English
pagine (da-a)	22-24
Numero di pagine	3
Rivista	THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
Volume	24
DOI	https://doi.org/10.3109/14767058.2011.601922
Stato di pubblicazione	Pubblicato - 2011

Keywords

Adult
Antifungal Agents
Chemoprevention
Child
Echinocandins
Humans
Infant
Intensive Care Units
Mycoses
Newborn
Pediatric
Risk Factors

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.3109/14767058.2011.601922

Altri file e collegamenti

Cita questo

@article{ac2918fb4c144a17a82734669643cd7f,

title = "Fungal infections in pediatric intensive care units",

abstract = "Pediatric fungal infections are associated with significant morbidity and mortality. Few adequately powered antifungal trials have been performed in neonates and children. Neonatologists and pediatricians are reliant on adult trials when managing candidemia. Recent guidelines from the Infectious Diseases Society of America recommend fluconazole or an echinocandin for empiric therapy in suitable candidates, with a preference for an echinocandin in patients with moderate-to severe disease, recent azole exposure, or high risk of C. glabrata or C. krusei infection",

keywords = "Adult, Antifungal Agents, Chemoprevention, Child, Echinocandins, Humans, Infant, Intensive Care Units, Mycoses, Newborn, Pediatric, Risk Factors, Adult, Antifungal Agents, Chemoprevention, Child, Echinocandins, Humans, Infant, Intensive Care Units, Mycoses, Newborn, Pediatric, Risk Factors",

author = "Gabriele Finco and Daniela Sanna and Maurizio Evangelista and Paolo Mura and Mario Musu",

year = "2011",

doi = "10.3109/14767058.2011.601922",

language = "English",

volume = "24",

pages = "22--24",

journal = "THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE",

issn = "1476-7058",

publisher = "Parthenon Publishing:Richmond House, White Cross, South Road LA1 4QX United Kingdom:011 44 1524 585700, EMAIL: [email protected], INTERNET: http://www.parthpub.com, Fax: 011 44 1524 66882",

}

TY - JOUR

T1 - Fungal infections in pediatric intensive care units

AU - Finco, Gabriele

AU - Sanna, Daniela

AU - Evangelista, Maurizio

AU - Mura, Paolo

AU - Musu, Mario

PY - 2011

Y1 - 2011

N2 - Pediatric fungal infections are associated with significant morbidity and mortality. Few adequately powered antifungal trials have been performed in neonates and children. Neonatologists and pediatricians are reliant on adult trials when managing candidemia. Recent guidelines from the Infectious Diseases Society of America recommend fluconazole or an echinocandin for empiric therapy in suitable candidates, with a preference for an echinocandin in patients with moderate-to severe disease, recent azole exposure, or high risk of C. glabrata or C. krusei infection

AB - Pediatric fungal infections are associated with significant morbidity and mortality. Few adequately powered antifungal trials have been performed in neonates and children. Neonatologists and pediatricians are reliant on adult trials when managing candidemia. Recent guidelines from the Infectious Diseases Society of America recommend fluconazole or an echinocandin for empiric therapy in suitable candidates, with a preference for an echinocandin in patients with moderate-to severe disease, recent azole exposure, or high risk of C. glabrata or C. krusei infection

KW - Adult

KW - Antifungal Agents

KW - Chemoprevention

KW - Child

KW - Echinocandins

KW - Humans

KW - Infant

KW - Intensive Care Units

KW - Mycoses

KW - Newborn

KW - Pediatric

KW - Risk Factors

KW - Adult

KW - Antifungal Agents

KW - Chemoprevention

KW - Child

KW - Echinocandins

KW - Humans

KW - Infant

KW - Intensive Care Units

KW - Mycoses

KW - Newborn

KW - Pediatric

KW - Risk Factors

UR - http://hdl.handle.net/10807/64385

UR - http://dx.medra.org/10.3109/14767058.2011.601922

U2 - 10.3109/14767058.2011.601922

DO - 10.3109/14767058.2011.601922

M3 - Article

SN - 1476-7058

VL - 24

SP - 22

EP - 24

JO - THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE

JF - THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE

ER -

Fungal infections in pediatric intensive care units

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo